3,4-Ethylenedioxymethcathinone

EDMC
Clinical data
Other names	EDMC; Ethylenedioxymethcathinone; 3,4-Ethylenedioxy-N-methylcathinone; β-Keto-EDMA; BK-EDMA; βk-EDMA
Drug class	Serotonin–norepinephrine–dopamine releasing agent
ATC code	None;
Identifiers
	IUPAC name 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(methylamino)propan-1-one;
CAS Number	802041-86-7;
PubChem CID	82100609;
ChemSpider	25630609;
UNII	CXT4C5UJ33;
ChEMBL	ChEMBL3604009;
CompTox Dashboard (EPA)	DTXSID001024649 ;
Chemical and physical data
Formula	C12H15NO3
Molar mass	221.256 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C(=O)C1=CC2=C(C=C1)OCCO2)NC;
	InChI InChI=1S/C12H15NO3/c1-8(13-2)12(14)9-3-4-10-11(7-9)16-6-5-15-10/h3-4,7-8,13H,5-6H2,1-2H3; Key:MRFMNGZRIIBJTB-UHFFFAOYSA-N;

3,4-Ethylenedioxymethcathinone, also known as EDMC or 3,4-ethylenedioxy-N-methylcathinone, is a monoamine releasing agent (MRA) of the phenethylamine, EDxx, and cathinone families related to methylone (3,4-methylenedioxymethcathinone; MDMC). It is the β-keto or cathinone analogue of 3,4-ethylenedioxymethamphetamine (EDMA).

EDMC acts as a serotonin–norepinephrine–dopamine releasing agent (SNDRA). Its EC₅₀Tooltip half-maximal effective concentration values for induction of monoamine release are 347 nM for serotonin, 327 nM for norepinephrine, and 496 nM for dopamine in rat brain synaptosomes. These potencies were about 1.4-fold, 2.2-fold, and 3.7-fold lower than those of methylone, respectively.

The drug was first described in 2015, whereas EDMA has been described much earlier.